創薬市場規模、シェア、成長分析、薬剤タイプ別、技術別、プロセス別、エンドユーザー別、地域別-産業別予測、2024～2031年

創薬の世界市場規模は、2022年に957億米ドルと評価され、2023年の1,020億2,000万米ドルから2031年には1,701億1,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは6.6％で成長する展望です。

世界の創薬市場は、疾病の蔓延、技術の進歩、個別化医療に対する需要の高まりに後押しされ、大幅な成長が見込まれています。革新的な研究開発イニシアチブは、疾患メカニズムを解明し、創薬を合理化するために、ゲノム、プロテオミクス、計算生物学を組み込んだ学際的アプローチで、新規創薬対象と効果的な治療法に焦点を当てています。さらに、高性能スクリーニング、人工知能、ビッグデータ分析などの最先端技術の活用は、医薬品開発の効率と成功率を大幅に向上させる。精密医療や標的治療が重視される中、市場は今後数年で目覚ましい拡大を遂げ、医療の重要な参入企業として位置づけられると考えられます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析と影響
  • 競争企業間の敵対関係
  • 代替品の脅威
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 供給企業の交渉力

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• 特許分析

創薬市場規模：薬剤タイプ別&CAGR（2024～2031年）

• 市場概要
• 低分子医薬品
• 生物製剤

創薬市場規模：技術別&CAGR（2024～2031年）

• 市場概要
• 高性能スクリーニング（HTS）
• 薬理ゲノム学
• コンビナトリアルケミストリー
• ナノ技術
• その他

創薬市場規模：プロセス別&CAGR（2024～2031年）

• 市場概要
• 対象の選択
• リード最適化
• ヒットからリードまでの識別

創薬市場規模：エンドユーザー別&CAGR（2024～2031年）

• 市場概要
• 製薬会社
• 契約研究機関（CRO）
• 学術研究機関
• その他

創薬市場規模&CAGR（2024～2031年）

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主要市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
• 製品ポートフォリオ分析
• セグメント別シェア分析
• 収益の前年比比較（2021～2023年）

主要企業プロファイル

• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• Johnson & Johnson
• Roche Holding AG
• Sanofi S.A.
• GlaxoSmithKline plc
• AstraZeneca plc
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.
• Biogen Inc.
• Boehringer Ingelheim GmbH
• Vertex Pharmaceuticals Incorporated
• Regeneron Pharmaceuticals, Inc.
• Novo Nordisk A/S

結論と推奨事項

Global Drug Discovery Market size was valued at USD 95.70 billion in 2022 and is poised to grow from USD 102.02 billion in 2023 to USD 170.11 billion by 2031, growing at a CAGR of 6.6% during the forecast period (2024-2031).

The Global Drug Discovery market is poised for substantial growth, fueled by rising disease prevalence, technological advancements, and a heightened demand for personalized medicine. Innovative R&D initiatives are focusing on novel drug targets and effective therapeutics, with an interdisciplinary approach that incorporates genomics, proteomics, and computational biology to unravel disease mechanisms and streamline drug discovery. Furthermore, the utilization of cutting-edge technologies such as high-throughput screening, artificial intelligence, and big data analytics significantly improves the efficiency and success rates of drug development. As the emphasis on precision medicine and targeted therapies intensifies, the market is set for remarkable expansion in the upcoming years, positioning it as a key player in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Market Segmental Analysis

Global Drug Discovery Market is segmented by drug type, technology, process, end user and region. Based on drug type, the market is segmented into small molecule drugs and biologic drugs. Based on technology, the market is segmented into high throughput screening (HTS), pharmacogenomics, combinatorial chemistry, nanotechnology and other. Based on process, the market is segmented into target selection, lead optimization and hit-to-lead identification. Based on end user, the market is segmented into pharmaceutical companies, contract research organizations (CROs), academic and research institutes and other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Drug Discovery Market

A key driver of the Global Drug Discovery market is the escalating prevalence of chronic and infectious diseases. The growing rates of conditions such as cancer, cardiovascular diseases, and various infectious illnesses have intensified the demand for innovative and effective pharmaceutical solutions. This surge in disease incidence compels pharmaceutical companies and research institutions to prioritize investment in drug discovery and development efforts, accelerating the creation of new treatments and therapies to address these pressing health challenges. As a result, the landscape of drug discovery is becoming increasingly vital in the quest for improved healthcare outcomes and enhanced patient well-being worldwide.

Restraints in the Global Drug Discovery Market

The Global Drug Discovery market faces significant restraints primarily due to the high costs and the lengthy nature of the drug development process. The journey from drug discovery to market approval is intricate and resource-intensive, necessitating considerable investments in research, clinical trials, and navigating regulatory requirements. This complexity, coupled with stringent safety and efficacy standards, extends development timelines and inflates overall expenses. As a result, these factors can hinder the accessibility and affordability of innovative medications, creating challenges for stakeholders involved in the drug discovery process and potentially impacting the market's growth trajectory.

Market Trends of the Global Drug Discovery Market

In the Global Drug Discovery market, a significant trend is the escalating integration of artificial intelligence (AI) and machine learning (ML) technologies, catalyzing a transformative shift in the drug development landscape. These innovative technologies facilitate the rapid analysis of extensive biological datasets, allowing for precise identification of drug-target interactions and streamlined workflows. AI-driven virtual screening and molecular modeling not only enhance the efficiency of drug candidate identification but also reduce overall costs and timelines associated with the drug discovery process. As a result, this trend is poised to improve success rates in clinical trials and foster the emergence of novel therapeutics, ultimately reshaping the pharmaceutical industry's approach to drug development.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis

Global Drug Discovery Market Size by Drug Type & CAGR (2024-2031)

• Market Overview
• Small Molecule Drugs
• Biologic Drugs

Global Drug Discovery Market Size by Technology & CAGR (2024-2031)

• Market Overview
• High Throughput Screening (HTS)
• Pharmacogenomics
• Combinatorial Chemistry
• Nanotechnology
• Other

Global Drug Discovery Market Size by Process & CAGR (2024-2031)

• Market Overview
• Target Selection
• Lead Optimization
• Hit-to-Lead Identification

Global Drug Discovery Market Size by End User & CAGR (2024-2031)

• Market Overview
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Other

Global Drug Discovery Market Size & CAGR (2024-2031)

• North America (Drug Type, Technology, Process, End User)
  • US
  • Canada
• Europe (Drug Type, Technology, Process, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Drug Type, Technology, Process, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Drug Type, Technology, Process, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Technology, Process, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation